Results 41 to 50 of about 311,440 (293)

Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. [PDF]

open access: yes, 2018
MicroRNAs, non-coding regulators of gene expression, are likely to function as important downstream effectors of many transcription factors including MYB. Optimal levels of MYB are required for transformation/maintenance of BCR-ABL-expressing cells.
Blandino, Giovanni   +15 more
core   +3 more sources

Acute myeloid leukemia: does sex matter? [PDF]

open access: yesLeukemia
Sex differences are increasingly recognized in the diagnosis and treatment of diseases. Biologically, the primary distinction between females and males is rooted in their sex chromosomes, XX in females and XY in males. While these chromosomal differences account for DNA-based variations, sex-related biological traits are complex and can be influenced ...
Jesse M. Tettero   +2 more
openaire   +3 more sources

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

open access: yesMolecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta   +10 more
wiley   +1 more source

Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria

open access: yesHaematologica, 2010
Background Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma. The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage markers ...
Ester Mejstrikova   +20 more
doaj   +1 more source

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. [PDF]

open access: yes, 2019
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or ...
Abruzzese, Elisabetta   +10 more
core   +2 more sources

Treatment-Related Acute Myeloid Leukemia Following Therapy for Acute Myeloid Leukemia.

open access: yesBlood, 2005
Abstract More than 50% of patients (pts.) who relapse from Acute Myeloid Leukemia (AML) have karyotypes different from those seen at primary diagnosis. This phenomenon might mirror clonal evolution or might result from antecedent therapies. In some cases completely different karyotypes might characterize treatment-related AML (t-AML).
Conradi, I.   +5 more
openaire   +2 more sources

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

open access: yesMolecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge   +17 more
wiley   +1 more source

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

open access: yesHaematologica, 2018
Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least
Rajeswaran Mani   +18 more
doaj   +1 more source

Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage

open access: yesFrontiers in Oncology, 2021
Acute leukemia of ambiguous lineage (ALAL) is a rare type of leukemia and represents an unmet clinical need. In fact, due to heterogeneity, substantial rarity and absence of clinical trials, there are no therapeutic guidelines available.
Gabriele Merati   +14 more
doaj   +1 more source

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. [PDF]

open access: yes, 2019
Introduction: Acute myeloid leukemia (AML) remains a disease with high mortality, especially for older patients and those with relapsed/refractory (R/R) disease.
Galkin, Maria, Jonas, Brian A
core   +1 more source

Home - About - Disclaimer - Privacy